Codex DNA

General Information
Business:

We believe that we are a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Our synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. 

Industry: LABORATORY ANALYTICAL INSTRUMENTS
Employees: 96
Founded: 2011
Contact Information
Address 9535 Waples Street, Suite 100, San Diego, CA 92121-2993
Phone Number (858) 228-4115
Web Address http://www.codexdna.com/
View Prospectus: Codex DNA
Financial Information
Market Cap $423.45mil
Revenues $7.9 mil (last 12 months)
Net Income $-21.6 mil (last 12 months)
IPO Profile
Symbol DNAY
Exchange NASDAQ
Shares (millions): 6.7
Price range $16.00 - $16.00
Est. $ Volume $106.7 mil
Manager / Joint Managers Jefferies/ Cowen/ KeyBanc Capital Markets
CO-Managers -
Expected To Trade: 6/18/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change